

LBA35

Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

J. Bourhis¹, Y. Tao², X. Sun³, C. Sire⁴, L. Martin⁵, X. Liem⁶, A. Coutte⁷, Y. Pointreau⁸, J. Thariat⁹, J. Miroir¹⁰, F. Rolland¹¹, M-C. Kaminsky¹², C. Borel¹³, A. Maillard², L. Sinigaglia¹⁴, J. Guigay¹⁵, E. Saada-Bouazid⁹, C. Even¹⁶, A. Aupérin¹⁷

¹ Radiation Oncology Department, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ² Radiation Oncology, Institut Gustave Roussy, Villejuif, France, ³ Franche-Comte, Hôpital Nord Franche-Comté - HNFC, Belfort, France, ⁴ Lorient, Centre Hospitalier de Bretagne Sud – Site du Scorff, Lorient, France, ⁵ Le Havre, Clinique des Ormeaux, Le Havre, France, ⁶ Lille, Centre Oscar Lambret, Lille, France, ⁷ Oncology Radiotherapy Department, CHU Amiens-Picardie - Site Sud, Amiens, France, ⁸ Le Mans, Centre Jean Bernard, Le Mans, France, ⁹ Nice, Centre Antoine Lacassagne, Nice, France, ¹⁰ Clermont-Ferrand, Centre Jean Perrin, Clermont-Ferrand, France, ¹¹ Medical Oncology Department, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, France, ¹² Lorraine, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France, ¹³ Strasbourg, Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, France, ¹⁴ Tours, GORTEC, Tours, France, ¹⁵ Medical Oncology Department, Centre Anticancer Antoine Lacassagne, Nice, France, ¹⁶ Head and Neck Department, Gustave Roussy, Villejuif, France ¹⁷ Head and Neck Cancer, Institut Gustave Roussy, Villejuif, France

Background

Based on a potential synergistic effect of anti-PD-L1 avelumab plus cetuximab and radiotherapy (RT), this combination was tested in a randomized phase III trial against 2 standards of care (SOC) in LA-SCCHN.

Methods

The trial comprised 2 cohorts of patients (pts) fit for cisplatin (3 cycles of 100 mg/m², Q3W) or unfit for cisplatin. The SOC was IMRT 70 Gy / 6.5 weeks with cisplatin in fit pts and with cetuximab in unfit pts (*Bonner, 2006*). In both cohorts, experimental arm (Exp) was 70 Gy / 6.5 weeks plus weekly cetuximab and avelumab 10 mg/kg at Day-7 and every 2 weeks during RT followed by avelumab for 12 months. The primary endpoint was progression-free survival (PFS). In Unfit pts, 115 events were needed / 277 pts to detect a HR of 0.62 (1-sided 0.05 type I error; power 80%). In Fit pts, 166 events were needed / 430 pts to detect a HR of 0.64 (2-sided 0.05 type I error; power 80%).

Results

Between 2017 and 2020, 707 pts were randomized. *For cisplatin unfit pts*, out of 277 pts, the number of PFS events was reached. Median age 67 years, 88% smokers, 61% oropharyngeal tumors (35% p16+), 24% stage III, 76% stage IV. Grade ≥ 3 AEs were 80% in both arms (p=0.91). Median follow-up was 21 months (IQR 15-28). PFS rate at 2 years (95%CI) was 44% (35%-53%) in Exp vs 31% (23%-40%) in Cetux-SOC (HR 0.85; p=0.15). Loco-regional progression at 2 years (95%CI) was 34% (26%-43%) in Exp vs 44% (35%-53%) in Cetux-SOC (HR = 0.83; p=0.34). Distant metastasis rate was lower in Exp (HR = 0.31, p=0.007). The 2-year OS rate (95%CI) was 58% (48%-67%) in Exp vs 54% in SOC (44%-64%) (HR 1.08; p=0.69). *For cisplatin fit pts*, out of 430 pts, the number of PFS events was not reached. The interim analysis for futility based on 89 events in 317 first pts showed a 1-year PFS rate (95%CI) of 64% (54%-72%) in Exp vs 73% in SOC-cisplatin (65%-81%): HR 1.27 (95%CI 0.83-1.93), crossing the futility boundary.

Conclusions

In cisplatin-Unfit pts, a favorable effect of adding avelumab to cetuximab was seen on PFS, local-regional control, distant metastases, but the primary endpoint on PFS was not met. In cisplatin-Fit pts, the futility boundary for efficacy was crossed, favoring SOC cisplatin.

Clinical trial identification

NCT02999087.

Legal entity responsible for the study

GORTEC.

Funding

GORTEC with a funding from MERCK Serono. This research was financially supported by Merck Serono S.A.S., Lyon, France, an

affiliate of Merck KGaA, as part of an alliance between Merck (CrossRef Funder ID: 10.13039/100009945) and Pfizer.

Disclosure

All authors have declared no conflicts of interest.

© European Society for Medical Oncology